Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Scribe Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Scribe Therapeutics Inc.’s stock price such as:

• Scribe Therapeutics Inc.’s current stock price and volume
• Why Scribe Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for SCTX from analysts
• SCTX’s stock price momentum as measured by its relative strength

About Scribe Therapeutics Inc. (SCTX)

Before we jump into Scribe Therapeutics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.

Want to learn more about Scribe Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Scribe Therapeutics Inc..

Scribe Therapeutics Inc.’s Stock Price as of Market Close

As of August 21, 2026, 4:00 PM, CST, Scribe Therapeutics Inc.’s stock price was $34.130.

Scribe Therapeutics Inc. is up 3.96% from its previous closing price of $32.830.

During the last market session, Scribe Therapeutics Inc.’s stock traded between $33.900 and $36.890. Currently, there are approximately 2.46 million shares outstanding for Scribe Therapeutics Inc..

Scribe Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Scribe Therapeutics Inc. Stock Price History

Scribe Therapeutics Inc.’s (SCTX) price is currently up 75.21% so far this month.

During the month of August, Scribe Therapeutics Inc.’s stock price has reached a high of $39.600 and a low of $19.090.

Over the last year, Scribe Therapeutics Inc. has hit prices as high as $39.600 and as low as $17.305.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Scribe Therapeutics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 21, 2026, there were analysts who downgraded Scribe Therapeutics Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Scribe Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Scribe Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Scribe Therapeutics Inc. (SCTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Scribe Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 21, 2026, Scribe Therapeutics Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Scribe Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Scribe Therapeutics Inc. Stock Price: Bottom Line

As of August 21, 2026, Scribe Therapeutics Inc.’s stock price is $34.130, which is up 3.96% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Scribe Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.